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The correlations between intramyocellular lipid (IMCL), decreased
fatty acid oxidation (FAO), and insulin resistance have led to the
hypothesis that impaired FAO causes accumulation of lipotoxic
intermediates that inhibit muscle insulin signaling. Using a skeletal
muscle-specific carnitine palmitoyltransferase-1 KO model, we
show that prolonged and severe mitochondrial FAO inhibition
results in increased carbohydrate utilization, along with reduced
physical activity; increased circulating nonesterified fatty acids; and
increased IMCLs, diacylglycerols, and ceramides. Perhaps more impor-
tantly, inhibition of mitochondrial FAO also initiates a local, adaptive
response in muscle that invokes mitochondrial biogenesis, compen-
satory peroxisomal fat oxidation, and amino acid catabolism. Loss of
its major fuel source (lipid) induces an energy deprivation response in
muscle coordinated by signaling through AMP-activated protein
kinase (AMPK) and peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC1α) to maintain energy supply for locomotion
and survival. At the whole-body level, these adaptations result in re-
sistance to obesity.
carnitine palmitoyltransferase | muscle | fatty acid | lipid | carbohydrate
Considerable evidence suggests that when oversupply of di-etary fat exceeds the storage capacity of adipose tissue, ec-
topic lipids accumulate in skeletal muscle, leading to “metabolic
stress” that induces insulin resistance. One prevailing theory is
that impaired skeletal muscle fatty acid oxidation (FAO) (1–4)
leads to cytosolic accumulation of lipotoxic intermediates that
are directly linked to defects in insulin signaling (5–11). Recent
findings counter this premise because they have shown that
models of insulin resistance consistently exhibit enhanced (not
reduced) FAO, as demonstrated by elevated incomplete β-oxi-
dation and accumulation of excess lipid-derived acylcarnitines
(12, 13). Supporting evidence was obtained using a whole-body
genetic approach to elevate levels of the endogenous carnitine
palmitoyltransferase-1 (Cpt1) inhibitor, malonyl-CoA (12). These
studies have led to the contrasting theory that lipid overload and
incomplete FAO within the mitochondria accelerate the pro-
gression of insulin resistance (14). Faced with a plethora of studies
supporting both hypotheses, a crucial question remains: “Is in-
hibition of mitochondrial FAO in skeletal muscle sufficient to
initiate development of insulin resistance?”
Cpt1 is essential for long-chain acyl-CoA transport into the
mitochondria, and lies at the nexus of both the lipotoxicity and
the mitochondrial overload hypotheses. If decreased FAO is a
root cause of lipotoxicity, then muscle-specific ablation of Cpt1b
activity should lead to impaired FAO, intramyocellular lipid
(IMCL) accumulation, and insulin resistance. In stark contrast,
the mitochondrial overload hypothesis suggests that decreased
Cpt1b activity would preserve insulin sensitivity by preventing
unbalanced overfueling of β-oxidation.
Characterization of the rare genetic disorders of Cpt1 and
Cpt2 has focused almost exclusively on the functional, rather
than metabolic, implications of sustained decrements to FAO.
However, dyslipidemia and insulin resistance have been ob-
served (15, 16). There have been a handful of studies that have
used pharmacological inhibition of Cpt1 to target insulin re-
sistance. The results are inconsistent and, in some cases, com-
pletely contradictory due to species/model differences and methods
of assessing insulin sensitivity (17–23). These studies also lack tissue
specificity and are generally of short duration and/or initiated after
development of insulin resistance/diabetes. The lack of tissue
specificity is most problematic. Decreased hepatic gluconeogenesis
as a result of liver Cpt1 inhibition may have effects on whole-body
insulin response independent of muscle (18, 22). Furthermore,
Cpt1 inhibition is associated with both cardiac hypertrophy and
hepatic steatosis (24–26). There have been attempts to inhibit the
muscle isoform, Cpt1b (23), specifically; however, long-term risks
of cardiac hypertrophy and mortality (27) suggest that pharmaco-
logical strategies must target specifically skeletal muscle.
Two of the studies have directly examined the impact of Cpt1
inhibition on the link between decreased FAO, increased IMCL,
and lipotoxicity-induced insulin resistance. Using the muscle-
selective Cpt1b inhibitor, oxfenicine, Keung et al. (23) showed
decreased diacylglycerol (DAG) and ceramide levels following
short-term treatment of obese mice. In contrast, Timmers et al.
(21) showed increased IMCL and DAG accumulation follow-
ing 8 d of treatment with the nonselective global Cpt1 in-
hibitor, etomoxir. These studies revealed short-term benefits in
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treatment of insulin resistance but contradictory conclusions
with respect to the role of lipotoxicity. In combination with the
studies by Conti et al. (22) using the liver-specific Cpt1 inhibitor,
teglicar, it is clearly important to understand the detailed mecha-
nisms underlying the impact of tissue-specific and isoform-selective
Cpt1 inhibition to develop therapeutic inhibitors with maximum
metabolic benefits and minimal side effects.
On the whole, the impact of prolonged inhibition of fatty acid
transport into skeletal muscle mitochondria has not been stud-
ied. To address this issue directly, we created mice with skeletal
muscle-specific deficiency of Cpt1b (Cpt1bm−/−).
Results
To determine the effects of impaired skeletal muscle mito-
chondrial FAO, we targeted the muscle-specific isoform, Cpt1b.
We crossed mice bearing floxed alleles of Cpt1b to Mlc1f-Cre
transgenic mice for specific ablation of Cpt1b in skeletal muscle,
but not cardiac tissue (28). Details of the Cpt1b targeting con-
struct and crossing scheme to generate floxed mice are shown in
Fig. S1. Cpt1bm−/− mice have normal levels of Cpt1b expression
in the heart, but there is near-complete knockdown of both gene
expression and Cpt activity in skeletal muscle (Fig. 1 A and B).
Mitochondrial FAO in Cpt1bm−/− mice is decreased significantly
to levels comparable to control mitochondria treated with the
inhibitor etomoxir (Fig. 1C).
Impairment of Mitochondrial FAO in Muscle Attenuates Development
of Adiposity. Cpt1bm−/− mice and control mice were fed a mod-
erate fat (25% kcal) breeder chow diet. Cpt1bm−/− mice are in-
distinguishable from controls at weaning and continue to gain
weight normally until 8–10 wk of age. Unexpectedly, Cpt1bm−/−
mice reach maximum body weight by 12–13 wk of age (Fig. 1D).
The difference in body mass is mainly attributed to changes in fat
mass. Control mice continue to accrue fat, whereas the fat mass
of Cpt1bm−/− mice is held at postpuberty levels (Fig. 1E). Im-
portantly, lean mass is similarly maintained at young adult levels
in Cpt1bm−/− mice, resulting in a slight difference from control
littermates by 20 wk of age (Fig. 1F).
To determine if food intake was causing the differences in fat mass,
food intake and body weight were measured over the period when
the fat mass between the control and Cpt1bm−/− mice is diverging.
Body weight and fat mass become significantly less in Cpt1bm−/−mice
compared with control mice (Fig. 2 A and B) well before food
intake becomes significantly less in Cpt1bm−/− mice compared
with control mice (Fig. 2C). Fat-free mass does not become sig-
nificantly less in Cpt1bm−/− mice compared with control mice until
about 100 d of age (Fig. 2D). Overall, these small differences in
daily food intake lead to a cumulative difference in food intake of
almost −15 g in the Cpt1bm−/− mice over the 8-wk period (Fig. 2F),
whereas body weight and fat mass were about 3 g less in Cpt1bm−/−
mice compared with control mice over the 8-wk period (Fig. 2E).
To see if there were direct effects in adipose tissue, we mea-
sured markers of mitochondrial number, lipolysis, β-oxidation,
adipocyte beiging/browning, and inflammation at 10 wk of age
(just before divergence of fat pad mass) and at 16 wk (a few
weeks after divergence of fat pad mass) in inguinal and epidid-
ymal fat depots. There were no significant effects observed in the
epididymal fat depot. In inguinal adipose tissue, Pnpla2/Atgl
trended higher in 10-wk-old Cpt1bm−/− mice but was significantly
higher by 16 wk. The β-oxidation enzyme, 3-hydroxyacyl–CoA
dehydrogenase, was significantly elevated at 10 and 16 wk in


























































































































































Fig. 1. Mice with skeletal muscle-specific Cpt1b deficiency have impaired mitochondrial FAO in muscle and decreased whole-body adiposity. (A) Tissue-
specific deletion in Cpt1bm−/− mice was confirmed by qRT-PCR analysis of Cpt1b mRNA (n = 5–7). Gastroc, gastrocnemius; iWAT; inguinal white adipose tissue.
(B) Skeletal muscle effects were confirmed in isolated mitochondria by Cpt activity assay. Cpt1bm−/− mitochondria were identical to normal mitochondria
treated with the Cpt1 inhibitor malonyl-CoA (M-CoA). (C) Impaired FAO was shown in isolated mitochondria using the [1-14C]palmitate-radiolabeled assay. B,
basal conditions; E, treated with the Cpt1 inhibitor etomoxir. Ablation of Cpt1b decreases weight gain (D) and fat accumulation (E), with maintenance of lean
mass (F) (n = 8–10 per group), in mice on a 25% fat chow diet. *P < 0.05 or **P < 0.01, genotype effect detected by ANOVA for multiple groups or by
Student’s t test. Results shown are representative of multiple independent experiments, and are expressed as mean ± SEM.


















































Cpt1bm−/− mice but was significantly higher by 16 wk (Fig.
S2A). Ucp-1, Cidea, and Elovl3 were all significantly elevated in
Cpt1bm−/− mice at 10 and 16 wk (Fig. S2B). TNF-α mRNA levels
were not different at 10 wk of age but TNF-α mRNA levels were
significantly less in Cpt1bm−/− mice by 16 wk (Fig. S2C).
Given the up-regulation of markers for FAO and uncoupling
in adipose tissue, one might expect increased energy expenditure
to account for decreased weight gain. However, Cpt1bm−/− mice
have overall reduced energy expenditure and activity (Fig. 3 A
and B). Analysis of covariance (ANCOVA) suggests that the
genotype effect on energy expenditure results from the reduced
activity of Cpt1bm−/− mice (Fig. 3C). In addition, the respiratory
exchange ratio (RER) is significantly higher in Cpt1bm−/− mice,
suggesting increased carbohydrate oxidation (Fig. 3D).
Cpt1bm−/− Mice Exhibit Moderate Myodegeneration and Impaired
Exercise Performance. Given that the Cpt1bm−/− mice are hypo-
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Fig. 2. Cumulative food intake is altered by skeletal muscle-specific ablation of Cpt1b. (A) Body weight diverges in Cpt1bm−/− mice by 70 d of age. Fat mass is
significantly less by 63 d of age (B), but cumulative food intake is not significantly reduced until 88 d of age (C). (D) Significant divergence of lean mass does
not occur until 100 d of age. Cumulative (56–119 d of age) weight gain (E) and food intake (F) are significantly reduced in Cpt1bm−/− mice. Data are expressed
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Fig. 3. Abrogation of Cpt1b decreases activity but increases carbohydrate use. Indirect calorimetry shows decreased energy expenditure (A) and activity level
(B) in Cpt1bm−/− mice (n = 7–8 at 5 mo of age). (C) ANCOVA analysis suggests that the genotype effect on energy expenditure is due to the decreased activity
of Cpt1bm−/− mice. Red symbols indicate Cpt1bfl/fl, and black symbols indicate Cpt1bm−/−. (D) RER values are higher, reflecting increased glucose utilization. D,
dark period; FFM, fat-free mass; FM, fat mass; L, light period; VO2, oxygen consumption.






































myoglobin in serum of Cpt1bm− /− mice (Fig. 4A). H&E and
phosphotungstic acid-hematoxylin (PTAH) staining shows multi-
focal degeneration and loss of cross-striations in some fibers by
3 mo of age (Fig. 4B). Mild functional implications appear to
manifest as mice age. We initially used rotarod performance, a
measure of neuromuscular coordination and muscle function, to
test for impairments, and found no difference in young (12-wk-
old) Cpt1bm−/− mice (Fig. 4C). We next used computerized gait
analysis to probe for more subtle alterations. No differences in gait
were detected in young Cpt1bm−/− mice, although mild gait dis-
turbances were apparent by 1 y of age (Fig. 4D). Despite the
decrement in mitochondrial FAO, treadmill-tested endurance is
only moderately decreased in Cpt1bm−/− mice at both young (12-
wk-old) and old (1-y-old) ages (Fig. 4E).
Impaired Muscle Mitochondrial FAO Increases Both Systemic and
IMCLs. Plasma nonesterified fatty acid (NEFA) and triacylglyc-
erols/triglycerides (TAGs) are significantly elevated, both prior
(2–3 mo) and subsequent (12 mo) to weight divergence (Fig.
5A). Bodipy staining of gastrocnemius reveals marked IMCL
accumulation in Cpt1bm−/− mice (Fig. 5B), which is visible as
large lipid droplets by EM (Fig. 5C). We next examined dif-
ferent lipid species in soleus and extensor digitorum longus
(EDL) muscle. Intramuscular TAGs are more than tripled in
Cpt1bm−/− soleus but are not statistically elevated in EDL (Fig.
5D). Several of the DAG species were significantly higher in
Cpt1bm−/− soleus (Fig. 5E). Likewise, most of the DAG species
were significantly elevated in Cpt1bm−/− EDL (Fig. 5E). Total
ceramides are approximately doubled in Cpt1bm−/− soleus, with
the C16, C18, and C18:1 species all being significantly increased
(Fig. 5F), whereas C16 is significantly increased in EDL (Fig.
5G). Lastly, gene expression of fatty acid transport (Cd36,
Fatp1), fatty acid binding (Fabp3), and lipid droplet forming
(Plin5) proteins is coordinately increased in all fiber types ex-
amined (soleus, EDL, red quadriceps, and white quadriceps; Fig.
5H and Table S1). Taken together, we can conclude that skeletal
muscle-specific Cpt1b depletion successfully recapitulates a
model of FAO impairment and lipid accumulation.
Impaired Muscle Mitochondrial FAO Does Not Inhibit Insulin Response.
Fasting insulin and glucose are significantly lower in Cpt1bm−/−
mice than control mice at 2 mo of age, when there is no difference
in body composition between Cpt1bm−/− mice and controls (Fig. 6
A and B). Insulin values in control mice increase with age, but
Cpt1bm−/− mice maintain low insulin values with age (Fig. 6A),
which is in agreement with less body fat. Although plasma NEFA
and TAGs and intramyocellular DAGs and ceramides are con-
sidered classic hallmarks of insulin resistance, there is no differ-
ence in response to a bolus of insulin. Insulin tolerance tests
(ITTs) show an equivalent insulin response in weight-matched
Cpt1bm−/− and control 10- to 12-wk-old mice (Fig. 6C) and 18-
to 20-wk-old Cpt1bm−/− mice (Fig. 6D). The older Cpt1bm−/−
mice have lower baseline glucose values, but the slopes after
insulin administration are essentially the same. Because results
from the ITT studies provide a picture of whole-body glucose
handling in response to insulin, we elected to perform studies
using isolated muscle strips to test the direct impact of Cpt1b
deficiency on insulin responsiveness. Consistent with the whole-
body ITT results, basal and insulin-stimulated glucose uptake in
isolated EDL and soleus muscle from Cpt1bm−/− mice was not sig-
nificantly different from control mice (Fig. S3). Consistent with the
whole-body and isolated muscle results, insulin-stimulated pAkt
(Ser473) is similar between Cpt1bm−/− and Cpt1bfl/fl mice after in-
jection of an insulin bolus (Fig. 6E). Likewise, insulin-stimulated
translocation of Glut4 to the plasma membrane is similar in both
genotypes (Fig. 6F). Despite high levels of DAG in Cpt1bm−/−
muscle, membrane localization of protein kinase C theta (PKCΘ)
is not significantly increased (Fig. 6G). Taken together, these data
strongly suggest that insulin signaling is intact in Cpt1bm−/− mice.
Cpt1bm−/− Mice Have Increased Carbohydrate Utilization. A consis-
tent hallmark of studies that have found beneficial effects of













































































































Fig. 4. Cpt1b depletion causes mild impairment of muscle function. (A) Serum levels of myoglobin are elevated in Cpt1bm−/− mice (n = 8–12). (B) H&E and PTAH
staining of gastrocnemius shows multifocal myodegeneration and loss of cross-striations in some fibers (in 3-mo-old mice). *Sites of myodegeneration. (Scale
bars: 50 μm.) (C) Rotarod performance is normal in 3-mo-old mice. (D) Computerized gait analysis reveals mild impairment in rear leg extension in 1-y-old Cpt1bm−/−
mice. (E) Treadmill endurance is significantly decreased in Cpt1bm−/− mice. *P < 0.05 by Student’s t test or ANOVA (n = 8–12 for behavioral assays).


















































favors glucose utilization. Although we did not observe any im-
provements or detriments to insulin-stimulated glucose uptake
in Cpt1bm−/− mice, glucose utilization appears to be enhanced.
Blood glucose levels are significantly lower in the Cpt1bm−/−
mice compared with controls during an i.p. glucose tolerance test
in both 10- to 12-wk-old mice and 18- to 20-wk-old mice (Fig. 7 A
and B). Likewise, we detected increased pyruvate dehydrogenase
(PDH) subunit-Pdha1 mRNA expression (Fig. 7C), increased
PDH activity (Fig. 7D), and increased complete oxidation of
pyruvate via the tricarboxylic acid (TCA) cycle in muscle ho-
mogenates (Fig. 7E). The increased carbohydrate oxidation is
further supported at the whole-body level, because the RER is
higher in Cpt1bm−/− mice (Fig. 3D). Furthermore, glycogen
levels are significantly reduced in red quadriceps but only mod-
erately reduced in white quadriceps (Fig. 7F). Taken together,
these data indicate that there is normal insulin action and in-
creased glycolytic flux in Cpt1bm−/− mouse muscle.
Impaired Mitochondrial FAO Leads to Mitochondrial Biogenesis. To
gain further insight into how impaired mitochondrial FAO af-
fects skeletal muscle metabolism in a chronic setting, we exam-
ined the activation of the energy sensor AMP-activated protein
kinase (AMPK) and mRNA expression of genes involved in the
regulation of energy and lipid metabolism, mitochondrial bio-
genesis, and function. Phosphorylation of the α-subunit of
AMPK at Thr-172 is significantly increased in Cpt1bm− /−
muscle (Fig. 8A). We found robust increases in expression of
the AMPK target peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (Pgc1α) in both red and white mus-
cles without changes in Pgc1β or PPARα mRNA (Fig. 8B and
Table S1). PGC1α is known as a master regulator of mitochon-
drial biogenesis. Consistent with AMPK/PGC1α activation, EM
in soleus muscle reveals large bands of mitochondria surround-
ing enlarged lipid droplets in Cpt1bm−/− mice (Fig. S4A). Mito-
chondria appear larger, with denser cristae. Measurement of
mitochondrial copy number (as the ratio of DNA copy number
of the mitochondrial genes, Cytb and Cox2, to the nuclear genes,
glucagon and β-globin) shows a 50% increase in mitochondrial
content in Cpt1bm−/− muscle compared with control mice (Fig.
8C). Additionally, we found a coordinate increase in expression
of genes associated with citric acid cycle and oxidative phos-
phorylation of mitochondria, including Cs, Ndufs8 (complex I),
Cox5a (complex IV), and SdhB (complex II) in Cpt1bm−/−
muscle (Fig. 8D and Table S1). Expression of genes related to
mitochondrial FAO, such as Hadha, Ech1, Cpt2, and Cact, is
























































































































































































































































































Fig. 5. Skeletal muscle-specific Cpt1b ablation alters local and systemic lipid homeostasis. (A) Plasma NEFA and TAG levels are increased in both young and
aged Cpt1bm−/− mice (n = 8–12). (B) Bodipy staining of gastrocnemius muscle shows IMCL accumulation (representative images, n = 4). (Scale bar: 100 μm.)
(C) EM imaging of soleus shows enlarged lipid droplets. (Scale bar: 10 μm.) (D) IMCL accumulation is accompanied by increased levels of TAGs in soleus, but not
in EDL (n = 4 per group). (E) Individual DAG species are also increased in soleus and EDL (n = 8–10 per group). Individual ceramide species are also increased in
soleus (F) and EDL (G) (n = 4 per group). (H) Expression of fatty acid transport, binding, and lipid droplet proteins is increased in Cpt1bm−/− muscle. *P < 0.05 or
**P < 0.01, differences detected by Student’s t test. Data are shown as mean ± SEM. Plasma was collected from mice that had been fasted for 4 h.






































with control mice (Fig. 8E). Additionally, a proteomic analysis of
muscle of Cpt1bm−/− mice compared with control mice confirmed
much of the mRNA analysis in Table S1, including a number of
mitochondrial proteins up-regulated in Cpt1bm−/− mice (Table 1).
Furthermore, upstream pathway analysis predicts activation of
PGC1α (Fig. 8F). Importantly, despite lifelong deficiency of the
mitochondrial enzyme Cpt1b, isolated mitochondria respire nor-
mally (Fig. S4B). Collectively, the EM, quantitative RT-PCR (qRT-
PCR), mitochondrial gene copy number, proteomics, and mi-
tochondrial function studies indicate adaptive biogenesis of
functional mitochondria in skeletal muscle of Cpt1bm−/− mice.
Metabolic Remodeling Leads to Alternative Substrate Utilization by
Mitochondria. To probe further the implications of decreased
mitochondrial FAO on metabolism within the muscle, we used
muscle homogenates to examine oxidation of other substrates.
Oxidation of the amino acid Leu is significantly increased in
Cpt1bm−/− muscle homogenate (Fig. 9A). Gene expression of the
Bcat2 and Bckdha enzymes is elevated (Fig. 9B), and metab-
olomics analysis reveals significant elevations in muscle levels of
nearly all amino acids tested (Fig. 9 C and D). This effect ap-
pears to be confined to muscle, because only Gly and citrulline
are elevated in serum (Fig. S5). Furthermore, propionylcarnitine
(C3) and succinylcarnitine (C4-DC) acylcarnitines are signifi-
cantly increased in Cpt1bm−/− muscle (Fig. S6). Production of C3
is commonly used as an indicator of amino acid catabolism,
because the breakdown of Val, Leu, Ile, and Met provides a
significant source of propionyl-CoA. Additionally, propionyl-
CoA enters the TCA cycle after it is carboxylated to form suc-
cinyl-CoA. As such, the increase in C4-DC and C3 in the present
study is quite likely a result of increased amino acid catabolism in
Cpt1bm−/− muscle. Globally, these analyses provide compelling
evidence that Cpt1b deficiency in muscle induces a localized
signal promoting mobilization and subsequent utilization of
amino acids as metabolic fuel.
Impaired Mitochondrial FAO Leads to Compensatory Peroxisomal
FAO. In addition to measuring FAO in mitochondria, we mea-
sured FAO in the whole-muscle homogenate. FAO in whole-
muscle homogenate is only slightly reduced in Cpt1bm−/− muscle
compared with control muscle (Fig. 9E). Peroxisomes are ca-
pable of processing a variety of long-chain and very-long-chain
fatty acids, and tend to be up-regulated in response to elevated
fatty acids, such as the environment in Cpt1b-deficient mice.
Expression of peroxisomal FAO genes, including Acox1, Peci,
Decr2, Pmp70, Pex19, and the medium-chain carnitine O-octa-
noyltransferase, Crot, is up-regulated in muscles from Cpt1bm−/−
mice (Fig. 9F and Table S1). We used extracellular flux analysis
to confirm that Cpt1bm−/− mitochondria are unable to oxidize
long-chain acyl-CoA esters but can respirate on long-chain
acylcarnitines, which could theoretically be supplied by peroxi-
somes (Fig. S4C). To confirm changes to peroxisomal function,
we measured oxidation of lignoceric acid (C24:0), which requires
peroxisomes to be catabolized (29). Results show that both total
and partial lignoceric acid oxidation is increased in Cpt1bm−/−
homogenates (Fig. 9G). Taken together, the data strongly sug-
gest that Cpt1bm−/− mice partially compensate for reduced mi-
tochondrial FAO by induction of peroxisomal FAO.
Discussion
There have been decades of conflicting literature regarding
pharmacological inhibition of Cpt for treatment of insulin re-
sistance. Given this ongoing confusing literature and the con-
trasting theories of the role of impaired vs. increased muscle
FAO on development of insulin resistance, we developed a
skeletal muscle-specific model of Cpt1b deficiency. As many


































































































































































Fig. 6. Depletion of Cpt1b in skeletal muscle does not impair whole-body insulin response or muscle insulin signaling. Blood glucose (A) and insulin levels
(B) are decreased in Cpt1bm−/− mice after a 4-h fast. There is no difference in response to an ITT in Cpt1bm−/− mice (n = 8–10) at 10–12 wk (C) or 18–20 wk (D).
(E) Insulin (Ins)-stimulated phosphorylation of Akt is unchanged in Cpt1bm−/− and Cpt1bfl/fl muscle (n = 4). (F) Similarly, insulin-stimulated translocation of
Glut4 to the membrane is unaffected by lack of Cpt1b (n = 3). (G) Membrane-associated levels of PKCΘ are not increased in Cpt1bm−/− mice (n = 4). Data are
shown as mean ± SEM. *P < 0.05 or **P < 0.01, Student’s t test. A.U., arbitrary units.


















































muscle to rely more heavily on carbohydrate for fuel. Enhanced
glucose disposal and elevated pyruvate oxidation as a result of
restricted FAO are consistent with substrate competition models
between glucose and fatty acids and the allosteric regulation of
hexokinase and PDH regulating both glucose uptake and oxi-
dation (14, 30). However, as with any homeostatic system, per-
turbations in one component cause compensatory adaptations.
Our results suggest that impaired skeletal muscle mitochondrial
FAO has complex effects that go beyond the regulation of glu-
cose uptake and oxidation.
These adaptations are vital to sustain energy supply to muscle
and are the result of several interrelated pathways. We suggest
that an energy deficit signal is induced that elicits a suite of ef-
fects, including mitochondrial biogenesis, compensatory oxida-
tion of fat by peroxisomes, and the use of amino acids for fuel.
To our knowledge, this study is the first report of enhanced
peroxisomal FAO in muscle following decreased mitochondrial
FAO, and the implications of prolonged reliance on peroxisomal
fat catabolism are unknown.
Another adaptation that appears to be directly affected by
reduced mitochondrial FAO is alterations in the cellular re-
sponse to accumulation of lipotoxic species. The loss of mi-
tochondrial FAO induces up-regulation of virtually every gene
examined related to fatty acid uptake and transport, lipolysis,
carnitine/acylcarnitine shuttle, and β-oxidation in Cpt1bm−/−
muscle (Table S1). However, the long-chain acyl-CoAs cannot
enter the mitochondria, leading to a massive accumulation of
IMCL. It has been previously suggested that IMCL, specifically
TAGs, are not detrimental, per se, but that it is rather the ac-
cumulation of lipotoxic DAGs and ceramides that impairs insulin
signaling. However, our results clearly show substantial increases
in both DAGs and ceramides, and yet no detriments to insulin
signaling. This result is at first counterintuitive; however, other
reports have found similar increases in lipotoxic species without
induction of insulin resistance, including the well-known ath-
lete’s paradox (31–34). Elevated DAGs have been found in en-
durance athletes with high insulin sensitivity (35). In these
studies, insulin sensitivity was associated both with specific DAG
species and with higher oxidative capacity (35), suggesting that
alterations to nutrient and energy balance may play a role in
determining the response to a lipotoxic environment. As a result,
one possible explanation for our findings is that activation of
energy/nutrient deprivation pathways is capable of overriding the
traditional lipid-induced decrements in insulin-stimulated glu-
cose uptake as a means to rescue energy production; however,










































































































































C D E F
Fig. 7. Glucose utilization is increased by abrogation of Cpt1b. Glucose disposal capacity is significantly improved in Cpt1bm−/− mice, as measured by a
glucose tolerance test, at both 10–12 wk (A) and 18–20 wk (B) (n = 8–10). (C) Expression of Pdha1 is increased. Both PDH (assayed with [1-14C]pyruvate) (D) and
complete pyruvate oxidation (Ox.) (measured with 3-[14C]pyruvate) (E) are significantly increased (n = 3–6, representative of multiple repeated experiments).
(F) Glycogen content is decreased, suggesting reliance on glucose utilization, in red quadriceps (R.Q.), but not in white quadriceps (W.Q.) (n = 4). *P < 0.05 or
**P < 0.01, differences detected by Student’s t test.



















44 22 6.37 + 2.65E-05
Generation of precursor
metabolites and energy
46 22 6.66 + 5.71E-05
Oxidative phosphorylation 33 18 4.78 + 1.39E-04
Cellular process 161 10 23.32 − 5.08E-02
Primary metabolic process 216 17 31.29 − 6.65E-02
Quantitative proteomics results from Cpt1bm−/− muscle were evaluated using the Panther statistical overrepresentation test for Gene Ontology (GO)
Biological Processes (www.pantherdb.org, version 8.0). The top five identified pathways are shown.






































unknown differences between specific species of DAGs and
ceramides and their subcellular locations are responsible for the
discrepancy (33, 36). Recent studies in humans have correlated
both individual DAG species, particularly saturated DAG, and
their subcellular localization to insulin resistance in humans (37,
38). In whole-muscle homogenates, we observe increases and a
few decreases in saturated, unsaturated, and mixed DAG species
in the Cpt1bm−/− muscle. Nevertheless, whether or not altered
distribution of lipotoxic species plays a role, our results argue
strongly that impaired mitochondrial FAO, even coupled with
chronic cellular lipid oversupply, is not sufficient to induce
insulin resistance.
In summary, to our knowledge, the first and almost foregone
results from decreased transport of fatty acids into the mito-
chondria are impaired mitochondrial FAO and the concomitant
increase in carbohydrate oxidation. More important are the
observed adaptations in muscle. To our knowledge, these results
provide the first observation in which decreased mitochondrial
FAO elicits a signal indicating a shortage of lipid in the muscle
causing the up-regulation of genes governing fatty acid uptake,
transport, storage, and oxidation, yet the lipids cannot enter the
mitochondria. However, the increased lipids are uncoupled to
their usual association with the interference in the insulin sig-
naling cascade. Understanding these uncoupling mechanisms
may be important in the treatment of type 2 diabetes. One could
conclude that the increased number of mitochondria and oxi-
dative capacity offset the lipid accumulation similar to the ath-
lete’s paradox, but because the mitochondria have reduced FAO
capacity, there may be other unexplored explanations. Perhaps
the most striking phenotype is that Cpt1bm−/− mice do not gain
or lose fat mass beyond 10–12 wk of age. Careful measurements
of food intake and body composition during the divergence in fat
mass between control and Cpt1bm−/− mice implicate decreased
food intake as a partial contributor. The finding that inhibition of
mitochondrial FAO in muscle increases oxidative and uncou-
pling capacity in inguinal fat suggests that energy may be dissi-
pated as heat. Elucidating the exact mechanisms that prevent
gain of fat mass in Cpt1bm−/− mice could have wide-ranging
implications in the obesity field.
Materials and Methods
Animal Studies. Animal studies were conducted at Pennington Biomedical
Research Center’s American Association for the Accreditation of Laboratory
Animal Care-approved facility, with mice receiving a standard chow diet,
composed of 20% (wt/wt) protein, 25% (wt/wt) fat, and 55% (wt/wt) car-
bohydrate (Purina Rodent Chow no. 5015; Purina Mills), and were approved
by the Institutional Animal Care and Use Committee.
Animal Procedures. Body composition was measured using a Bruker NMR
Minispec (Bruker Corporation). Food intake was measured as described by
Kruger et al. (39), with slight modifications. Plasma collections were per-
formed by submandibular bleed. Glucose tolerance tests were performed
following a 4-h fast by i.p. injection of 20% D-glucose (40 mg of glucose per
mouse). ITTs were done in the fed state, using an i.p. dose of 0.04 units (U)
per mouse. For insulin signaling studies, mice were fasted overnight (∼16 h)
and given an i.p. injection of insulin (1.0 U/kg of body weight) or saline, and
tissues were collected 10 min later. Tissue processing and isolated muscle
experiments are described in SI Materials and Methods. Indirect calorimetry
was done in a 16-chamber Oxymax system (Columbus Instruments) as de-
scribed by Albarado et al. (40). Behavioral studies were performed with
slight modifications from the method of Wicks et al. (41). Endurance was
measured following three habituation sessions; speed was increased from
6 m·min−1 by 0.5 m·min−1 at 5-min intervals until exhaustion.
Metabolic Profiling. ELISA kits were used for measurement of insulin (Ultra





















































































































Fig. 8. PGC1α pathway leads to mitochondrial biogenesis in Cpt1bm−/− muscle. (A) Phosphorylation of AMPKα at Thr172 is increased by FAO deficiency.
(B) Gene expression of PGC1α and PPARγ, but not PGC1β or PPARα mRNA, is increased in Cpt1bm−/− muscle. Mitochondrial proliferation is induced, as shown
by increased mtDNA copy number (quadriceps, n = 11) (C), coordinate up-regulation of mitochondrial gene expression (D), and increased expression of
mitochondrial FAO genes (E). (F) Proteomics analysis (n = 7–8) detected significant overrepresentation of mitochondrial genes, and mechanistic network
analysis predicts activation of a PGC1α signaling pathway. *P < 0.05 or **P < 0.01, differences detected by Student’s t test. Data are shown as mean ± SEM.


















































and triglyceride-H; Wako Diagnostics). Isolation of lipid and quantification
of TAGs and ceramides were performed as described by Obanda et al. (42).
DAGs were measured as described by Wang et al. (43). Glycogen was mea-
sured using a commercial kit (65620; Abcam) according to the manu-
facturer’s instructions. Measurement of acylcarnitines, amino acids, and
proteomics is described in SI Materials and Methods.
qRT-PCR. Total RNA from mouse tissue was isolated using an RNeasy Mini Kit
(Qiagen) and DNase digested. cDNA synthesized with the iScript cDNA syn-
thesis kit was used for qRT-PCR with the SYBR Green system (Bio-Rad). DNA
was isolated using a DNA/RNA Mini Kit (Qiagen). Primer details are provided
in Table S2.
Substrate Oxidation Assays. Red quadriceps or mixed gastrocnemius muscle
homogenates were prepared as previously described (44). Mitochondrial
isolation was performed as described by Frezza et al. (45); the IBm2 buffer
was modified to 70 mM sucrose, 200 mM mannitol, 5 mM EGTA/Tris (pH 7.4),
and 10 mM Tris·HCl (pH 7.4). Fatty acid and pyruvate oxidation was assessed
using whole-muscle homogenates or isolated skeletal muscle mitochondria
as in the study by Hulver et al. (46); etomoxir was used at a final concen-
tration of 100 μM. Peroxisomal FAO was measured from [1-14C]lignoceric
acid (20 μM) as previously shown (44). Capture of 14CO2 from [U-14C]Leu
(100 μM) was measured over the course of 2 h in reaction media (pH 7.8) con-
sisting of the following: 100 mM sucrose, 10 mM Tris·HCl, 10 mM K2HPO4,
80 mM KCl, 1 mM MgCl2·6H2O, 2 mM L-carnitine, 0.2 mM malate, 0.08 mM
pyridoxal phosphate, 0.4 mM α-ketoglutarate, 1 mM DTT, 0.1 mM nicotin-
amide-adenine dinucleotide, 2 mM ATP, and 0.05 mM CoA.
CPT Activity Assay. CPT activity was assayed using isolated mitochondria
(120 μg per well) according to principles outlined by Bieber et al. (47). Mito-
chondrial assays are described in SI Materials and Methods.
Immunofluorescence and Bodipy Staining. Gastrocnemius muscles were frozen
in a mixture of Optimal Cutting Temperature Compound (Sakura) and Trag-
acanth (Spectrum). Sectioned samples were fixed in 4% paraformaldehyde
solution (Invitrogen), incubated in a 1:100 dilution of Bodipy in PBS (Invitrogen),
and mounted in Citifluor (Ted Pella, Inc.). PTAH and H&E staining was per-
formed by standard protocols in formalin-fixed tissues at the Louisiana State
University-AgCenter Histology Core.
EM. EMwas performed at the SocolofskyMicroscopy Center at Louisiana State
University. Materials were fixed in 2% (wt/vol) glutaraldehyde/1% (wt/vol)
formaldehyde and then postfixed in 2% (wt/vol) osmium tetroxide, en bloc

















































































































































































































































Fig. 9. Cpt1b deficiency in skeletal muscle remodels energy metabolism, leading to compensatory amino acid catabolism and peroxisomal FAO. Cpt1bm−/−
muscles use amino acids as an alternative energy source, as shown by enhanced Leu oxidation in muscle homogenates (A) and increased expression of genes
involved in amino acid metabolism (B). Leu oxidation was measured from [U-14C]Leu in gastrocnemius homogenate (n = 4). (C and D) Consistent with amino
acid catabolism in Cpt1bm−/− muscle, levels of nearly all amino acids are elevated. (E) Although mitochondrial FAO is decreased, there is no reduction in FAO in
quadriceps muscle homogenates (measured with [1-14C]palmitate; n = 3, representative of multiple independent experiments). B, basal; E, treated with the
Cpt1 inhibitor etomoxir. (F) Up-regulation of peroxisomal activity is suggested by increased expression of peroxisomal FAO genes (n = 5–7). (G) Increased
peroxisomal capacity for FAO is shown by enhanced oxidation of lignoceric acid (C24:0), which can only be oxidized by peroxisomes. Lignoceric acid (partial
and total) oxidation was measured from [1-14C]lignoceric acid in gastrocnemius homogenate (n = 4). *P < 0.05 or **P < 0.01, differences detected by Student’s
t test. Data are shown as mean ± SEM.






































(70 nm) were mounted on collodion-coated copper grids, stainedwith Reynolds
lead citrate, and imaged with a JEOL 100CX transmission electron microscope.
Statistical Analysis. Data were analyzed by t test, ANOVA/repeated measures
ANOVA, with Bonferroni posttests using GraphPad Prism 5 software. ANCOVA
analysis was performed using JMP software from SAS. The P value was set at
<0.05 a priori.
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